LEADERS IN ONCOLOGIC INTERVENTIONS ECIO 2015€¦ · learning. The Video Learning Sessions, whose debut in 2014 was well received, will be featured again this year, addressing liver,

C RSE

LEADERS IN ONCOLOGIC INTERVENTIONS

www.ecio.org

ECIO 2015April 22-25, 2015Nice, France

Sixth European Conference on Interventional Oncology

PRELIMINARYPROGRAMME

Cardiovascular and Interventional Radiological Society of Europe

ECIO is now well established as an annual event, and the interest shown and the feedback received have demonstrated that the move to an annual format was a wise one. The field of interventional oncology is growing rapidly, and ECIO offers a structured space in which practitioners can stay abreast of the latest developments and learn new techniques.

Oncology is a field that requires inter-disciplinary collaboration. Patients now benefit from a vast array of specialist knowledge, but this brings its own challenges, and ECIO is striving to ensure its educational programme reflects and supports a

collaborative approach. This includes working with diverse partner societies on a variety of joint sessions, and we are delighted that such sessions will again be offered.

The president of the Japanese Society of Interventional Radiology, which has been strongly focused on interventional oncology for many years, will be delivering this year’s Honorary Lecture. Dr. Yasuaki Arai, who has been at the forefront of the discipline in the Asia-Pacific, will be giving a speech entitled Beyond the evidence – the true goal of interventional oncology.

Advisory Board

Andreas Adam (UK)Thierry de Baère (FR)Johannes Lammer (AT)Riccardo Lencioni (IT)Jan H. Peregrin (CZ)Jim A. Reekers (NL)

COMMITTEES

Scientific Programme Committee

Thierry de Baère (FR), ChairpersonThomas K. Helmberger (DE), Deputy ChairpersonCarmen Ayuso (ES)Anna-Maria Belli (UK)Patrick Chevallier (FR)Alban Denys (CH)Afshin Gangi (FR)Jean-François H. Geschwind (US)Patrick Haage (DE)Robert A. Morgan (UK)Franco Orsi (IT)Philippe L. Pereira (DE)

Local Host Committee

Patrick Chevallier (Nice), ChairpersonGuillaume Baudin (Nice)Sébastien Bommart (Montpellier)Pascal Chabrot (Clermont-Ferrand)Afshin Gangi (Strasbourg)Jean-Yves Gaubert (Marseille)Boris Guiu (Montpellier)Hicham Kobeiter (Créteil)Sébastien Novellas (Nice)Frank Pilleul (Lyon)Hervé Trillaud (Bordeaux)Vincent Vidal (Marseille)

A. Adam C. Ayuso A.-M. Belli T. de BaèreP. Chevallier A. Denys A. Gangi J.-F.H. Geschwind

LE AD E R S I N O N CO LO G I C

The meeting has grown over the years, and now encompasses a wide range of session formats, which cater to all styles of learning. The Video Learning Sessions, whose debut in 2014 was well received, will be featured again this year, addressing liver, kidney and lung cancer, as well as the important topic of pain management.

Clinical management is an essential pre-requisite for offering a robust interventional oncology service. To support inter-disciplinary collaborations and negotiations, a number of Multidisciplinary Tumour Boards will be held, discussing various liver and lung cancer cases.

Alongside a wide range of technical advances, ECIO 2015 will cover both established and experimental applications, such as musculoskeletal tumours, lung metastases, and thyroid, adrenal and prostate lesions.

The Mediterranean city of Nice offers an excellent location for the congress. Located within driving distance of Italy, Switzerland and Spain, the city’s fame as a beauty spot also translates into a multitude of flight connections.

We look forward to welcoming you to Nice!

On se retrouve à Nice!

Content

Preliminary Faculty

Honorary Lecture

Incentive Programme

6 years of ECIO – 6 reasons to attend

Programme Overview

Scientific Programme

Hands-on Workshops

Registration / CME / Important Addresses

Accommodation / City Map

2345

6-78-20

222324

T.K. Helmberger J. LammerP. Haage R. Lencioni F. OrsiR.A. Morgan P.L. Pereira J.A. ReekersJ.H. Peregrin

I NTE RV E NTI O N S

2 European Conference on Interventional Oncology

P r e l i m i n a r y P r o g r a m m e

Preliminary Faculty

Amoretti N. Nice/FR Anderson C. London/UK Anty R. Nice/FR Arai Y. Tokyo/JP Arnold D. Freiburg/DE Ayuso C. Barcelona/ES Baek J.H. Seoul/KR Bezzi M. Rome/IT Bilbao J.I. Pamplona/ES Bize P.E. Lausanne/CH Breen D.J. Southampton/UK Callstrom M.R. Rochester, MN/US Caridi J.G. New Orleans, LA/US Carrafiello G. Varese/IT Chevallier P. Nice/FRClasen S.R. Tübingen/DE Cornelis F. Bordeaux/FR Crocetti L. Pisa/IT de Baère T. Villejuif/FR den Brok M. Nijmegen/NL Denys A. Lausanne/CH Deschamps F. Villejuif/FR Dupuy D.E. Providence, RI/US Duran R. Lausanne/CH Faivre S. Lausanne/CH François E. Nice/FR Gangi A. Strasbourg/FR Garcia-Mónaco R.D. Buenos Aires/AR Garnon J. Strasbourg/FR Gervais D. Boston, MA/US Geschwind J.-F.H. Baltimore, MD/US Gillams A. London/UK Goldberg N. Jerusalem/IL Guiu B. Montpellier/FR Helmberger T.K. Munich/DEInaba Y. Nagoya/JP Jereczek-Fossa B. Milan/IT Kelekis A.D. Athens/GR Kenny L.M. Brisbane/AU

Krokidis M. Cambridge/UK Lencioni R. Pisa/IT Lewandowski R.J. Chicago, IL/US Littrup P.J. Detroit, MI/US Mahnken A.H. Marburg/DE Majno P. Geneva/CH Malagari K. Athens/GR Malek N.P. Tübingen/DE Manca A. Candiolo/IT Marquette C. Nice/FR McCrone P. London/UK Mindjuk I. Dachau/DE Miyayama S. Fukui/JP Monfardini L. Milan/IT Napoli A. Rome/IT Narayanan G. Miami, FL/US Orsi F. Milan/IT Palussière J. Bordeaux/FR Paradis V. Clichy/FR Pelage J.-P. Caen/FR Pereira P.L. Heilbronn/DE Ricke J. Magdeburg/DE Rilling W.S. Milwaukee, WI/US Ronot M. Clichy/FR Ryan A.G. Waterford City/IE Sabharwal T. London/UK Salem R. Chicago, IL/US Samuels S.L. Miami, FL/US Sangro B. Pamplona/ES Sofocleous C.T. New York, NY/US Sommer C.M. Heidelberg/DE Suh R.D. Los Angeles, CA/US Tanaka T. Kashihara/JP Tapping C. Oxford/UK Tsoumakidou G. Strasbourg/FR Wood B.J. Bethesda, MD/US Woodrum D.A. Rochester, MN/US Yamakado K. Tsu/JP Zech C.J. Basel/CH

Preliminary Facultyas per printing date – subject to change

ECIO 2015 3

Yasuaki Arai is Director of, and Chief of the Department of Diagnostic Radiology at, the National Cancer Center Hospital in Tokyo. He also currently serves as the President of the Japanese Society of Interventional Radiology (JSIR).

During his residency in internal medicine, Dr. Arai became interested in chemotherapy, and pursued the path of becom-ing a “medical oncologist”, a term that was not yet particularly well-recognised at the time. He was not satisfied with the clinical results achieved with systemic chemotherapy, and so began exploring the possibility of using a different approach. This ultimately resulted in the invention of an implantable port system, as well as the development of a technique involving placing a catheter via the left subclavian artery for hepatic arterial infusion chemotherapy, a concept first addressed in a publication in a Japanese medical journal in 1983.

A year later, Dr. Arai shifted direction, focusing on intervention-al radiology at the Aichi Cancer Center, where he practiced for 20 years. Many younger radiologists have joined this institute over the years in order to receive training in interventional radiology.

Dr. Arai founded the Japanese Society of Implantable Port-Assisted Regional Treatment in 1986, aiming to facilitate the nationwide sharing of knowledge about interventional radiology and the role the specific technique could play in treating cancer. He has led the society, which provides a forum for specialists to exchange information across departments, ever since. The im-plantable port system was ultimately introduced in the article entitled “Management of patients with unresectable metastases from colorectal and gastric cancer employing an implantable port system” (Cancer Chemother. Pharmacol. 31:S990102. 1992).

Dr. Arai has pursued the development of new IR devices and techniques in order to offer better treatment options through-out his entire career. In addition to his work on the implantable port system and the hepatic arterial chemotherapy tech-nique, in 1992, he collaborated with Toshiba Medical Systems Corporation to develop the prototype of a diagnostic system, consisting of a fluoroscopy and a CT scanner, which is currently well-known as the Angio-CT suite. Furthermore, he has devised various approaches that apply interventional radiological tech -niques for palliative care purposes, including using a trans-jugular trans-hepatic peritoneovenous shunt for the management of

Yasuaki Arai

Honorary Lecture Beyond the evidence – the true goal of interventional oncology

Thursday, April 2310:30-11:30

refractory ascites; embolisation of various tracts and fistula; the percutaneous creation of bilio-intestinal anastomosis; and the creation of an extra-anatomic splenoportal for bleeding ectopic varices. Their application in palliative care stemmed from his 20 years of experience at the Aichi Cancer Center, where he treated thousands of patients suffering from progressive cancer.

Strengthening interventional radiology’s evidence base has been another major priority for Dr. Arai during the past 20 years. In 2002, he set up the Japan Interventional Radiology in Onco-logy Study Group (JIVROSG) in order to facilitate pursuing evi-dence on interventional oncology. Twenty-six clinical studies have been conducted so far, and JIVROSG has published articles on some of these studies, including one entitled “Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian coopera-tive study between Japan and Korea” (J Vasc Interv Radiol. 24: 490-500, 2013). JIVROSG has set itself the challenge of conduct-ing randomised trials that compare interventional radiological procedures to the best treatments available for palliative care.

Yasuaki Arai has been an associate editor for the Journal of Vascular and Interventional Radiology, the Cardiovascular and Interventional Radiology Asia-Pacific Journal of Clinical Oncology, and the International Cancer Conference Journal, and has also served as reviewer for several journals. He is a member of several governmental committees in Japan, including for the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. Dr. Arai has been a board member of the Japanese Society of Inter ventional Radiology for years, helping to establish and expand the reach of interventional radiology in Japan. He is currently its president, and aims to help ensure that interven-tional radiological procedures become evidence-based, standard treatments, as well as to further IR’s global scope.

Since 2004, Dr. Arai has served in the Department of Diagnostic Radiology in the National Cancer Center Japan. Even after leading the institute as the hospital’s director, he remains engaged with the outpatient clinic and with IR procedures.

In his spare time, Dr. Arai enjoys mountain climbing and cooking, activities that reflect his preference for tackling challenges with both knowledge and the proper technique.

ECIO 2015 Honorary Lecture

€100,000 Education Grant

CIRSE supports the “Referring Physician” programme with €100,000!

The ECIO Incentive Programme allows radiologists with a full registration for ECIO 2015 in Nice to invite their referring physician to the conference free of charge.

The first 100 referring physicians to sign up will receive free registration and up to €1,000 travel support.

For further information and registration please go to www.ecio.org

Incentive ProgrammeECIO 2015

1 Video Learning Sessions

This interactive session format made its debut lastyear, and due to the hugely positive response received, it has been decided to extend the sessions on offer this year, to cover liver interventions, lung and kidney therapies, and pain management, guiding you through the procedures step by step.

2 Best IO Papers

Interventional oncology is a growing field, and both new advances and data supporting existing thera-pies are of the utmost importance. The Best IO Papers session will round up some of the most interesting research from the past year, providing you with a concise overview of current trends.

3 Joint Session with ESMO

To both reflect and enhance the multidisciplinary nature of interventional oncology, joint sessions are held with other medical societies. These provide valuable insights into colla borative possibilities. Our long-time partner, the European Society for Medical Oncology will join us again for a fascinating session on Friday.

4 Multidisciplinary Tumour Boards

Much as they do in the hospital setting, these tumour boards enable participants to actively discuss treat-ment strategies for specific HCC and lung cancer cases. Guided by the mixed-specialty panel, the audience can vote on optimal therapeutic approaches and discuss the likely outcomes.

5 Referring Physician Incentive Programme

For many years, the Referring Physician Programme has been enabling interventionists to bring their non-radiologist colleagues to the meeting, where they can see the range of therapies on offer, and the evidence for their use, first-hand. Will you be bringing your colleague to Nice this year?

6 Nice la Belle

‘Nice the Beautiful’ is a wonderful destination for a congress – its picturesque surroundings and mild climate have resulted in the third busiest airport in France, many international train connections, and the second largest hotel capacity in the country. The per-fect place for a congress: in hosting ECIO 2015, the city has plenty to inspire not only impressionists, but also interventionists!

6 years of ECIO 6 reasons to attend


CF 502Symptomatic cancer treatment

08:00

15

30

45

09:00

15

30

45

10:00

15

30

45

11:00

15

30

45

12:00

15

30

45

13:00

15

30

45

14:00

30

45

15:00

15

30

45

16:00

15

30

45

17:00

15

30

45

18:00

15

e-voting recommended for EBIR preparation

Wednesday, April 22

CF 101Early-stage HCC

CF 201Intermediate HCC

TF 202Top tips

TA-HoW 1Image-guided tumour ablation – MSK

IS 401Multidisciplinary Tumour Board: HCC

TF 402 Ablation: current status and future horizons

TA-HoW 2 Image-guided tumour ablation – lung

Coffee break

Satellite Symposia

Coffee break

p8

p9 p9 p9

p10

p8 p9

p8

Lunch break

Break

Satellite Symposia

CF 501How to follow up patients: clinical and imaging

Thursday, April 23

p10

Coffee break

Satellite Symposia

Lunch break

Break

IS 1101Multidisciplinary Tumour Board: lung

JS 1102 Essence of inter-ventional oncologyJoint session with JSIR

TA-HoW 4Image-guided tumour ablation – kidney

p13 p13 p13

Satellite Symposia

Coffee break

CF 801Lung metastases

VL 802How I do it: liver

HL 901Honorary Lecture

PS 902The best IO papers of 2014

TA-HoW 3Image-guided tumour ablation – liver

CF 1202Fundamentals of oncology

p14

CF 1201Ablation: evidence for expanding the boundaries

p13

p12 p12

p12

p12 p12

Satellite Symposia

15

30

45

19:00

30

45

08:00

15

30

45

09:00

15

30

45

10:00

15

30

45

11:00

15

30

45

12:00

15

30

45

13:00

15

30

45

14:00

30

45

15:00

15

30

45

16:00

15

30

45

17:00

15

30

45

18:00

15

Saturday, April 25

IS 2101Management of complications II

VL 2201How I do it: pain management

Coffee break

CF: Clinical Focus Session HL: Honorary Lecture HoW: Hands-on Workshop IS: Interactive Session JS: Joint Session PS: Paper SessionTF: Technical Focus Session VL: Video Learning Session

Friday, April 24

Coffee break

Satellite Symposia

Lunch break

Break

VL 1801How I do it: lung and kidney

CF 1802Quality pays: clinical excellence saves money

p17 p17

Satellite Symposia

Coffee break

CF 1501MSK tumours

JS 1502Colorectal liver metastases ECIO invites ESMO

CF 1601Kidney cancer

CF 1602Intra-arterial therapies: what is the evidence?

JS 1902Molecular oncology and translation into the clinicJoint session with WCIO

p18

IS 1901Management of complications I

p17

p16 p16

Satellite Symposia

p16 p16

p20

p20

15

30

45

19:00

30

45


8 Wednesday, April 22

Wednesday, April 22

08:30-10:00 CF 101 Clinical Focus Session Main Auditorium Early-stage HCC

101.1 Pathology of early HCC V. Paradis (Clichy/FR) 101.2 Imaging of early HCC C.J. Zech (Basel/CH) 101.3 Why and how to biopsy N.P. Malek (Tübingen/DE) 101.4 What to do when on the waiting list for transplantation P. Majno (Geneva/CH) 101.5 Evidence from literature: resection vs. ablation for early HCC R. Lencioni (Pisa/IT)

10:30-12:00 CF 201 Clinical Focus Session Main Auditorium Intermediate HCC

201.1 Critical appraisal of EASL vs. Hong Kong classification R. Salem (Chicago, IL/US) 201.2 Where does ablation fit in intermediate stage HCC? P. Chevallier (Nice/FR) 201.3 Drug-eluting beads vs. conventional TACE T.K. Helmberger (Munich/DE) 201.4 Where does radioembolisation fit in intermediate stage HCC? B. Sangro (Pamplona/ES) 201.5 Current evidence of systemic therapy in intermediate stage HCC R. Anty (Nice/FR)

10:30-12:00 TF 202 Technical Focus Session Auditorium 2 Top tips

202.1 Radioembolisation: preparation A. Denys (Lausanne/CH) 202.2 Radioembolisation: treatment R.J. Lewandowski (Chicago, IL/US) 202.3 DEB TACE J.G. Caridi (New Orleans, LA/US) 202.4 Lung ablation G. Carrafiello (Varese/IT) 202.5 Kidney ablation F. Orsi (Milan/IT) 202.6 Spinal ablation G. Tsoumakidou (Strasbourg/FR) 202.7 Bone consolidation F. Deschamps (Villejuif/FR)

European Conference on Interventional Oncology

ECIO 2015 99Wednesday, April 22

10:30-12:00 TA-HoW 1 Hands-on Workshop HoW Room Image-guided tumour ablation – MSK

Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE) Instructors: A. Gangi (Strasbourg/FR), A.D. Kelekis (Athens/GR), A. Manca (Candiolo/IT)

13:00-14:30 Satellite Symposia

15:00-16:30 IS 401 Interactive Session Main Auditorium Multidisciplinary Tumour Board: HCC

Co-ordinator: R. Lencioni (Pisa/IT) Panellists: R. Anty (Nice/FR), P. Chevallier (Nice/FR), T.K. Helmberger (Munich/DE), P. Majno (Geneva/CH), W.S. Rilling (Milwaukee, WI/US), R. Salem (Chicago, IL/US)

15:00-16:30 TF 402 Technical Focus Session Auditorium 2 Ablation: current status and future horizons

402.1 Radiofrequency ablation B.J. Wood (Bethesda, MD/US) 402.2 Electroporation N. Goldberg (Jerusalem/IL) 402.3 Microwaves P.L. Pereira (Heilbronn/DE) 402.4 HIFU I. Mindjuk (Dachau/DE) 402.5 Cryoablation D.J. Breen (Southampton/UK) 402.6 Immunomodulation with ablation M. den Brok (Nijmegen/NL)

15:00-16:30 TA-HoW 2 Hands-on Workshop HoW Room Image-guided tumour ablation – lung

Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE) Instructors: S.R. Clasen (Tübingen/DE), A. Gillams (London/UK), C.T. Sofocleous (New York, NY/US)

recommended for EBIR preparatione-voting


10 Wednesday, April 22

17:00-18:30 CF 501 Clinical Focus Session Main Auditorium How to follow up patients: clinical and imaging

501.1 Radioembolisation for CRC T.K. Helmberger (Munich/DE) 501.2 TACE for HCC J.-F.H. Geschwind (Baltimore, MD/US) 501.3 Ablation of colorectal liver metastases B. Guiu (Montpellier/FR) 501.4 Bone ablation M.R. Callstrom (Rochester, MN/US) 501.5 Ablation of lung metastases J. Ricke (Magdeburg/DE)

17:00-18:30 CF 502 Clinical Focus Session Auditorium 2 Symptomatic cancer treatment

502.1 Systemic pain medication: a practical guide to be announced 502.2 Evidence-base of radiation therapy for pain L.M. Kenny (Brisbane/AU) 502.3 Nerve blocks G. Tsoumakidou (Strasbourg/FR) 502.4 Percutaneous management of pleural effusion P.E. Bize (Lausanne/CH) 502.5 Percutaneous management of malignant ascites C. Tapping (Oxford/UK)



ECIO investigates…

Hepatocellular carcinoma, the most common type of liver cancer, is a growing problem worldwide, due largely to the increasing prevalence of chronic liver disease. Considerable progress with respect to detection, diagnosis, surveillance and treatment has improved outcomes, but HCC is nonetheless the third leading cause of cancer deaths. Relatively few patients are eligible for surgery, and systemic therapy alone is of limited value. Interventional radiology has greatly broadened treatment options, with ablation poten-tially curative for early-stage HCC. However, most patients still present with intermediate or advanced forms of the disease, meaning palliation plays a predominant role.

Early-stage HCCDetection and Diagnosis

Early detection and an accurate diagnosis greatly affect a patient’s prognosis. CT and MRI are most commonly used to de tect the disease. Thanks to advances in both imaging and surgical techniques, small, early-stage HCCs have increasingly been de- tected, biopsied, resected and subjected to patholo gi cal exami na-tions, helping practitioners better understand their histolo gical features. With imaging techniques enabling more accurate dia-g noses, and appreciation of the diagnostic value of contrast wash-out growing, the need for tissue confirmation has also waned. Nonetheless, in daily practice, definitive diagnoses often remain challenging, particularly with respect to small nodules. Presen-tations dedicated to pathology, imaging and biopsies will pro-vide delegates with up-to-date information of pathology in early HCC; outline typical and atypical aspects of the disease on CT and MRI, as well as limitations of the two imaging techniques; and will address when it is still necessary to perform a biopsy.

Curative Treatment Options

Ablation offers a potentially curative option for patients with small localised HCCs. However, critics note that overall, long-term survival rates are higher after resection, and that recur-rence remains an issue, while proponents emphasise that it in volves fewer complications and shorter hospital stays. In other cases, only liver transplantation is potentially curative, but pa tients are either ineligible or confronted with a donor shortage.

Lectures focusing on ablation, resection and transplantation will outline strategic considerations involved in deciding with which of these approaches to proceed, and scrutinise the strength and weaknesses of both the methods and of studies that seek to compare them.

Intermediate HCCClassi�cations

The Barcelona Clinic Liver Cancer classifications, while widely endorsed, have also long been criticised for providing insuf-ficient options for practitioners confronting intermediate HCC. Now some medical centres are considering adopting the new Hong Kong Liver Cancer classification, and guidelines issued by the European Association for the Study of the Liver and the European Organization for Research and Treatment of Cancer are also receiving much attention. A lecture dedicated to these two approaches will outline their structure and review how they impact daily practice for IRs.

Percutaneous Treatment Options

Transarterial chemoembolisation remains the standard treat-ment for intermediate HCC, but most expect the use of drug- eluting beads (DEB-TACE) to further improve results. In the mean-time, radioembolisation has become an important therapy op tion, but still faces scepticism regarding its competitive effi ca cy for HCC beyond the early stage. Treating intermediate HCC with ablation is an even newer concept. Three presentations will close -ly examine these approaches, presenting results ob tained and limitations confronted, including from a comparative perspective.

Systemic Therapy

The multi-faceted nature of clinical practice for intermediate HCC includes systemic therapy with drugs, and several on-going trials are now evaluating the potential of combining such therapy with loco-regional treatments. A presentation on sys-temic therapies will explore the biological background, outline results achieved, and address at which point such treatments are best combined with IR procedures.

Colorectal liver metastases Practitioners have long emphasised the importance of tailored therapy, but does the concept represent reality or mere hope? A session jointly held with the European Society for Medical Onco -logy will consider this important question in the context of colo-rectal liver metastases, in addition to reviewing other aspects of CRCLM, including the current status of systemic therapy, tumour response following TACE/SIRT, and radioembolisation for palliation.

Other sessionsA Hands-on Workshop will tackle image-guided tumour ablation in the liver, providing a tangible introduction to the procedure and the devices it involves, and a Video Learning Session will demon-strate how to perform a wide variety of percutaneous liver treatments.

Liver Cancer


12 Thursday, April 23 European Conference on Interventional Oncology

Thursday, April 23


08:30-10:00 CF 801 Clinical Focus Session Auditorium 2 Lung metastases

801.1 How to evaluate lung function before and after surgery, SBRT and ablation? C. Marquette (Nice/FR) 801.2 Surgery in lung metastases to be announced 801.3 Is ablation of lung metastases a first line therapy? A. Gillams (London/UK) 801.4 Imaging follow-up after treatments: surgery, SBRT, ablation R.D. Suh (Los Angeles, CA/US) 801.5 Evidence from comparative trials for lung metastases L. Monfardini (Milan/IT)

08:30-10:00 VL 802 Video Learning Session Main Auditorium How I do it: liver

802.1 Liver ablation + venous occlusion T. de Baère (Villejuif/FR) 802.2 Combined cTACE and ablation L. Crocetti (Pisa/IT) 802.3 DEB-TACE K. Malagari (Athens/GR) 802.4 Y-90 J.I. Bilbao (Pamplona/ES) 802.5 PVE P.E. Bize (Lausanne/CH)

10:30-11:30 HL 901 Honorary Lecture Main Auditorium

Laudation: T. de Baère (Villejuif/FR)

901.1 Beyond the evidence – the true goal of interventional oncology Y. Arai (Tokyo/JP)

11:30-12:00 PS 902 Paper Session Main Auditorium The best IO papers of 2014

10:30-12:00 TA-HoW 3 Hands-on Workshop HoW Room Image-guided tumour ablation – liver

Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE) Instructors: L. Crocetti (Pisa/IT), A.H. Mahnken (Marburg/DE), F. Orsi (Milan/IT)

13Thursday, April 23


15:00-16:30 IS 1101 Interactive Session Auditorium 2 Multidisciplinary Tumour Board: lung

Co-ordinator: A. Gillams (London/UK) Panellists: M. Bezzi (Rome/IT), L. Monfardini (Milan/IT), S.L. Samuels (Miami, FL/US), R.D. Suh (Los Angeles, CA/US)

15:00-16:30 JS 1102 Joint Session Main Auditorium Essence of interventional oncology Joint session with the Japanese Society of Interventional Radiology (JSIR)

1102.1 Concept of TACE based on micro-vasculature of HCC S. Miyayama (Fukui/JP) 1102.2 Intra-arterial infusion therapy – background and challenges T. Tanaka (Kashihara/JP) 1102.3 Interventional palliative treatment Y. Inaba (Nagoya/JP) 1102.4 Ablation – combination with other IR techniques K. Yamakado (Tsu/JP) 1102.5 Clinical trials for evidences of IO Y. Arai (Tokyo/JP)

15:00-16:30 TA-HoW 4 Hands-on Workshop HoW Room Image-guided tumour ablation – kidney

Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE) Instructors: D.J. Breen (Southampton/UK), C.M. Sommer (Heidelberg/DE)

17:00-18:30 CF 1201 Clinical Focus Session Main Auditorium Ablation: evidence for expanding the boundaries

1201.1 Thyroid J.H. Baek (Seoul/KR) 1201.2 Breast J. Palussière (Bordeaux/FR) 1201.3 Adrenal D.E. Dupuy (Providence, RI/US) 1201.4 Lymphnodes A. Gillams (London/UK) 1201.5 Prostate D.A. Woodrum (Rochester, MN/US)

ECIO 2015




Thursday, April 23

17:00-18:30 CF 1202 Clinical Focus Session Auditorium 2 Fundamentals of oncology

1202.1 Conventional chemotherapy D. Arnold (Freiburg/DE) 1202.2 Targeted therapy: what an interventional oncologist should know S. Faivre (Lausanne/CH) 1202.3 Phase I, II, III trials: do you really know the differences? E. François (Nice/FR) 1202.4 How to define response in interventional oncology trials M. Ronot (Clichy/FR) 1202.5 How endpoints in interventional oncology may differ from medical oncology trials R. Salem (Chicago, IL/US)



In recent years, ECIO has witnessed an increase in the number of speakers and sessions addressing pulmonary cancers, both pri ma ry and metastatic. This is clearly a growing area of interest for prac ti-tioners of interventional oncology, and as the pool of case re- ports grows, so the indications for its use are growing ever clearer.

This year’s congress will feature a number of sessions presenting this data, and offering valuable advice on patient selection and optimal delivery. These will cover a range of therapeutic applica tions, including thermal ablation, mechanical ablation and embolisation.

Lung metastasesCurrently, the main clinical areas of investigation for image-guid ed lung therapies are stage I non-small cell lung cancer (NSCLC) and pulmonary metastases. The latter are a particu larly important area of investigation, as they are among the most fre quently oc curring metastases and are found in approximately 50% of autop sy patients. Metastatic lesions, by their very nature, are often small and multi-nodular, posing challenges for surgical resection.

Two promising alternatives for pulmonary metastases are abla-tion and stereotactic body radiation therapy (SBRT), and these will be examined more closely in Thursday’s Lung metastases Clinical Focus Session.

SBRT is an extra-cranial radiation therapy which is delivered in a single or small number of fractions. It is highly precise, and offers the possibility of controlling for target motion. Despite its advantages, there remain some limitations regarding the uncertainty of target definition, dose escalations and inaccu-rate patient positioning. No clinical trials have yet been completed, and further investigation is needed.

Likewise, the evidence supporting ablation is far from complete, but early data indicates that it entails few complications, has short recovery times and is repeatable. Most importantly of all, the literature has demonstrated no deterioration of pulmonary function, which is an important consideration in both the cura-tive and palliative setting. Ensuring clear margins remains a chal -lenge, although using a thermocouple can improve outcomes.

The latest evidence for both therapies, and technical advice of evaluating lung function and performing adequate follow-up, will be discussed in this Clinical Focus Session, as well as in the dedicated How to follow up patients: clinical and imaging session taking place on Wednesday.

However, ablative techniques are not the only IR procedure available, and preliminary studies into the palliative use of intra-arterial techniques have shown promise. This is mainly used for symptomatic control of bleeding in patients with

lung metastases, and is achieved by selective embolisation of the branches of the pulmonary artery. Friday’s Clinical Focus Session on Intra-arterial therapies: what is the evidence? will examine the current data for its use in the pulmonary setting and others.

Multidisciplinary decision-makingClearly, for both metastatic and primary disease, much more research is needed. Even when clearer indications are eventually defined, each individual patient will still present with a unique set of circumstances and determining the optimal therapy (or therapy combination) is best done in a multidisciplinary setting.

To demonstrate and encourage this process, a Multidisciplinary Tumour Board session will be devoted to examining lung cancer cases. Practitioners from a range of specialties will be represen-ted, and the session will undoubtedly be informative for all involved in this field.

ComplicationsAblative therapies are not without risk, and it is essential that practitioners are aware of possible complications, and how to deal with them. Pneumothorax is the most common com-plication, but is easily managed with quiet respiration, and adequate pain control and sedation.

The second most frequent complication is pleural effusion, which will be explicitly addressed in Wednesday’s Symptomatic cancer treatment session. Generally, exercising due caution will prevent this occurring, but if faced with pleural effusion, meth-ods such as observation, thoracentesis and pleural catheter placement can be employed. Pain is managed with anti-inflam-matory agents, narcotics, anti-convulsant drugs, intercostal nerve block, and hot or cold packs; those wishing to learn more about this topic should attend Saturday’s Video Learning Session, How I do it: pain management, for step-by-step guidance through the use of the PleurX system.

Pseudo-aneurysms and delayed acute haemoptysis are very rare and cavitation can occur in large ablations, but does not necessarily indicate infection. A detailed discussion of all lung ablation complications will be given by noted expert Robert Suh, in Saturday’s interactive session, Management of complications II.

The full spectrumThe programme for this year’s ECIO will cover the full spectrum of image-guided therapies for pulmonary cancers, from patient selection to follow-up. Various ablation modalities will be discussed in a variety of settings, with a Hands-on Workshop on Image-guid-ed tumour ablation – lung giving participants an op por tunity to fa- miliarise themselves with a number of devices, and a Video Learn-ing Session guiding attendees through pulmonary cryoablation.

Lung Cancer

16

Friday, April 24


08:30-10:00 CF 1501 Clinical Focus Session Auditorium 2 MSK tumours

1501.1 Evidence for ablation in local control M.R. Callstrom (Rochester, MN/US) 1501.2 Evidence for radiation therapy in local control B. Jereczek-Fossa (Milan/IT) 1501.3 When does HIFU fit in? A. Napoli (Rome/IT) 1501.4 Bone consolidation: cementoplasty vs. osteosynthesis F. Deschamps (Villejuif/FR) 1501.5 When to use embolisation in combination with ablation A.G. Ryan (Waterford City/IE)

08:30-10:00 JS 1502 Joint Session Main Auditorium Colorectal liver metastases ECIO invites the European Society for Medical Oncology (ESMO) Programme to be announced.

10:30-12:00 CF 1601 Clinical Focus Session Main Auditorium Kidney cancer

1601.1 Renal mass: surveillance protocols, indications for biopsy and thresholds for treatment to be announced 1601.2 Evidence-based nephron-sparing surgery C. Anderson (London/UK) 1601.3 Evidence-based ablation vs. resection outcomes D.J. Breen (Southampton/UK) 1601.4 Systemic and adjuvant treatment in RCC to be announced 1601.5 Follow-up after ablation: imaging and clinical D. Gervais (Boston, MA/US)

10:30-12:00 CF 1602 Clinical Focus Session Auditorium 2 Intra-arterial therapies: what is the evidence?

1602.1 Liver metastases from melanoma: what is the role of intra-arterial therapies today? P.L. Pereira (Heilbronn/DE) 1602.2 Neuroendocrine liver metastases: which intra-arterial therapy for which patient? B. Guiu (Montpellier/FR) 1602.3 Intra-arterial therapy in lung tumours: where do we stand? J.-P. Pelage (Caen/FR) 1602.4 Cholangiolar carcinoma: the relative role of TACE vs. systemic therapy W.S. Rilling (Milwaukee, WI/US) 1602.5 Intra-arterial therapy in liver metastases: the 5 best papers of the past year R.D. Garcia-Mónaco (Buenos Aires/AR)

Friday, April 24 European Conference on Interventional Oncology

17Friday, April 24


15:00-16:30 VL 1801 Video Learning Session Main Auditorium How I do it: lung and kidney

1801.1 Lung RFA/MWA D.E. Dupuy (Providence, RI/US) 1801.2 Lung cryoablation P.J. Littrup (Detroit, MI/US) 1801.3 Kidney RFA/MWA F. Cornelis (Bordeaux/FR) 1801.4 Kidney cryoablation D.J. Breen (Southampton/UK) 1801.5 Percutaneous pancreas IRE G. Narayanan (Miami, FL/US)

15:00-16:30 CF 1802 Clinical Focus Session Auditorium 2 Quality pays: clinical excellence saves money

1802.1 Improve quality without added cost: patient pathway in IO A. Denys (Lausanne/CH) 1802.2 Improve quality without added cost: a structured IO report A. Gangi (Strasbourg/FR) 1802.3 Cost effectiveness in patient care: what is it, and how to measure it in interventional oncology? P. McCrone (London/UK) 1802.4 Disinvestment in medicine, and the need for evidence L.M. Kenny (Brisbane/AU) 1802.5 The science underpinning interventional oncology: how should we prove the value of what we do? R. Lencioni (Pisa/IT)

17:00-18:30 IS 1901 Interactive Session Main Auditorium Management of complications I

1901.1 Liver TACE S.L. Samuels (Miami, FL/US) 1901.2 Liver ablation P. Chevallier (Nice/FR) 1901.3 Radioembolisation A.H. Mahnken (Marburg/DE) 1901.4 GI complications T. Sabharwal (London/UK)

ECIO 2015




Friday, April 24

17:00-18:30 JS 1902 Joint Session Auditorium 2 Molecular oncology and translation into the clinic Joint session with the World Conference on Interventional Oncology (WCIO)

1902.1 Oncogenic pathways and their relevance to interventional oncology N. Goldberg (Jerusalem/IL) 1902.2 Tumour hypoxia B.J. Wood (Bethesda, MD/US) 1902.3 Immunomodulation and radioembolisation J. Ricke (Magdeburg/DE) 1902.4 Tumour metabolism J.-F.H. Geschwind (Baltimore, MD/US) 1902.5 Image-guided drug activation R. Duran (Lausanne/CH) 1902.6 DNA repair inhibitor A. Denys (Lausanne/CH)



Interventional radiological treatment of tumours in solid organs, such as primary or secondary liver tumours or renal cell carcinoma (RCC) is already well established, or has at least gained major attention in interdisciplinary discussions. Moreover, interventional radiology is well established in the musculoskeletal (MSK) field, mainly in the fields of pain man-agement (e.g. perineural or facet joint infiltration), but a wide range of tumour-related interventions are also well accepted.

Primary MSK cancers are comparatively rare, but bone meta-stases, which can derive from any type of primary cancer but occur frequently in prostate, breast and lung cancer patients, are quite common. Furthermore, there are a substantial num-ber of benign tumours, such as osteoid osteoma and osteo-blastoma, typically occurring in patients aged between 5 and 25 years, or rarer benign tumours, such as desmoid tumours and haemangiomas, which may present a more aggressive growth pattern.

Interventional radiology can be performed for curative or palliative/symptomatic treatment in functionally stable or unstable, benign or malignant tumours. Furthermore, in many cases interventional therapy offers local tumour control (e.g. by thermal destruction), minimisation of fracture risks by stabilisa-tion (e.g. by cementoplasty) together with pain therapy (e.g. destruction of nociceptors).

In general, all these interventional techniques can be used in combination with other therapies (e.g. chemotherapy, radia-tion therapy or surgery), but can also offer the possibility of symptom relief where other therapies have failed.

Thermal ablationThermal ablative techniques, in particular radiofrequency ablation (RFA), are the method of choice for benign lesions such as osteoid osteoma and many haemangiomas (mostly vertebral localisation), but are also applied for destruction in malignant tumours. The extensive experience in applying RFA to bone tumours confirms RFA as an easy and safe technique in many different skeletal localisations with a low risk of com-plications. The database for other thermal ablative techniques (microwave ablation, cryoablation, HIFU or laser) is still very limited and is often only single-centre-based, and more data is needed to establish the clinical value of each of these techniques.

Transvascular techniquesTransarterial tumour embolisation in hypervascularised tumours (e.g. bone metastasis from RCC) is used to make another therapy easier (e.g. for reducing blood loss during surgery) or for debulking in large symptomatic tumours where other therapies have failed or are not amenable.

Augmentation therapiesMusculoskeletal tumours, whether primary or metastatic, can often compromise the structural integrity of the affected bone. Whether this occurs due to invasion and displacement of the healthy tissue, or as a result of therapeutic intervention, stabilising the bone is important for both patient mobility and resolution of potential pain.

A number of percutaneous approaches are currently used, ranging from cementoplasty to the image-guided percutane-ous placement of screws or pins (osteosynthesis), or frequently, a combination of the two. As with thermal ablative procedures, knowledge of the local anatomy and real-time monitoring is essential to avoid complications.

This important topic will be addressed in Wednesday’s Top tips session, where speakers will address both spinal ablation and bone consolidation, along with other therapies of growing interest.

Pain therapy/managementBeside thermal ablation of osteoid osteomas, which can be very painful, most MSK interventional procedures need no specific pain management and can be performed under local anaesthesia or mild analgo-sedation. It can be even crucial to get the immediate feedback from the patient with respect to pain to avoid serious complications. Nevertheless, interven-tional therapy of many painful MSK lesions results in immediate pain relief – almost “on the table”.

Risks and complicationsLocal interventional therapy in MSK structures is straight-forward in most cases. Nevertheless, in some cases inter-disciplinary assistance is mandatory to get the right access to a specific lesion (e.g. by mechanical bone drill). The procedure can also be challenging due to the close anatomical proximity of crucial structures (e.g. nerve structures) necessitating special techniques for cooling (e.g. perfusion with a coolant, skin cooling pads) or dislodgement (e.g. hydrodissection).

MSK programme at ECIO 2015To ensure comprehensive educational opportunities, the ECIO 2015 programme will be covering MSK tumour therapies in a range of session formats. A Hands-on Workshop, Clinical Focus Sessions, Interactive Sessions and even a Video Learning Session will guide delegates through both the theory and the practice of a range of treatments. Most importantly of all, the evidence for their use will be examined alongside radiothera-peutic and surgical options, equipping those practicing MSK interventions with the skills needed to be clinically involved in their hospital’s tumour boards.

MSK tumours



Saturday, April 25

Saturday, April 25

08:30-10:00 IS 2101 Interactive Session Main Auditorium Management of complications II

2101.1 MSK tumour management A. Gangi (Strasbourg/FR) 2101.2 Liver ablation C. Ayuso (Barcelona/ES) 2101.3 Kidney ablation M. Krokidis (Cambridge/UK) 2101.4 Lung ablation R.D. Suh (Los Angeles, CA/US)

10:30-12:00 VL 2201 Video Learning Session Main Auditorium How I do it: pain management

2201.1 Splanchnic neurolysis A.D. Kelekis (Athens/GR) 2201.2 Vertebroplasty and ablation J. Garnon (Strasbourg/FR) 2201.3 PleurX G. Narayanan (Miami, FL/US) 2201.4 Pelvic osteosynthesis N. Amoretti (Nice/FR) 2201.5 Hypogastric neurolysis to be announced

The EBIR is a highly valuable quali�cation in interventional radiology, based on the European Curriculum and Syllabus for IR.

Sessions especially suited for EBIR preparation are highlighted in the ECIO 2015 Scienti�c Programme (pages 6-20).

Special preparation courses for the EBIR

Apply for the 2015 EBIR examinations now online!For detailed information regarding examination dates and entry criteria, please visit our website at www.cirse.org/ebir

EB I R European Board of Interventional Radiology

European Board of Interventional Radiologyc/o CIRSENeutorgasse 9, 1010 Vienna, [email protected]/ebir

C RSE

Certify your expertise!


22 Hands-on Workshops European Conference on Interventional Oncology

Image-guided tumour ablationCo-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE)

Image courtesy of Prof. Laura Crocetti

This hands-on workshop will give you the opportunity to participate in interactive sessions based on case presentations. Four workshops will each target a specific organ (MSK, lung, liver and kidney). The cases are presented by leading ablation experts with many years of experience in an informal inter-active setting allowing for questions and discussion. A range of different ablation systems (RFA, cryotherapy and microwave ablation) and some image guidance technology will be accessible to the participants during the sessions for ex-vivo demonstrations.

Learning objectives– To learn how to handle different energy sources and the

respective equipment for tumour ablation– To obtain a good understanding of the range of available

ablation techniques and their proper clinical application– To learn what factors are predictive of success and failure

in order to determine the best indication and optimal combination of therapies

– To understand the main reported complications of ablation and the basics of preventing and managing them

– To learn about “tips and tricks” with the use of clinical cases– To generally learn about the indications of other medical

and surgical treatments

TA-HoW 1 Wednesday, April 22MSK 10:30-12:00

Instructors: A. Gangi (Strasbourg/FR), A.D. Kelekis (Athens/GR), A. Manca (Candiolo/IT)

TA-HoW 2 Wednesday, April 22Lung 15:00-16:30

Instructors: S.R. Clasen (Tübingen/DE), A. Gillams (London/UK), C.T. Sofocleous (New York, NY/US)

TA-HoW 3 Thursday, April 23Liver 10:30-12:00

Instructors: L. Crocetti (Pisa/IT), A.H. Mahnken (Marburg/DE), F. Orsi (Milan/IT)

TA-HoW 4 Thursday, April 23Kidney 15:00-16:30

Instructors: D.J. Breen (Southampton/UK), C.M. Sommer (Heidelberg/DE)

LocationHoW Room

Please note that participants need to register in advance at an extra cost of €75.

ECIO 2015 23

Reduced CIRSE Member registration is only available for members of CIRSE (Cardiovascular and Interventional Radiological Society of Europe) in good standing.

Method of paymentRegistration fees are to be paid in Euros (€) by:- Bank transfer or Credit Card (Visa or Mastercard)

Registration / CME / Important Addresses

European Accreditation will be applied for at the EACCME (European Accreditation Council for Continuing Medical Education). The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

CME Credit Allowance

Congress VenueNice Acropolis Convention Centre1 Esplanade Kennedy06300 Nice, France

Organising SecretariatCIRSE Central OfficeNeutorgasse 91010 Vienna, AustriaPhone: +43 1 904 2003Fax: +43 1 904 2003 30E-mail: [email protected] Web: www.ecio.org

Important Addresses

E-mail ContactsFor general enquiries about the ECIO 2015 meeting, please send an e-mail to [email protected].

In case of queries concerning registration for the ECIO 2015 meeting, please send an e-mail to [email protected].

For information about the scientific programme of ECIO 2015, please send an e-mail to [email protected].

RegistrationOnline registration (secured payment) for ECIO 2015 is available at www.ecio.org.

Please note that your registration must be submitted and full payment needs to be received by the respective registration deadlines. Otherwise the respective next higher fee shall be due. Furthermore please be advised that incomplete registra-tions (not containing full name, e-mail and address) cannot be processed.

Subscription to ESIRonlineWe are extending year-round ESIRonline access to non-members: purchase your one-year subscription for ESIRonline (www.esir.org), for only €30 together with your registration to ECIO 2015.*

Registration Fees

Early – until January 22, 2015 (23:59 CET)CIRSE Member € 390Non-Member € 590Resident / Nurse / Radiographer* € 250Undergraduate Medical Student** € 0

Until February 19, 2015 (23:59 CET)CIRSE Member € 550Non-Member € 790Resident / Nurse / Radiographer* € 385Undergraduate Medical Student** € 0

After February 19, 2015CIRSE Member € 750Non-Member € 860Resident / Nurse / Radiographer* € 420Undergraduate Medical Student** € 0

* To be accompanied by a certificate, signed by the head of department.

* CIRSE Members in good standing benefit from full access to ESIRonline.

Registration fees inclusive of 20% VAT

Under French Fiscal Regulations, VAT (20%) is charged on invoices to all customers who do NOT have a valid French VAT number. This applies to customers based in all countries inside and outside the EU. Only if a valid French VAT number is provided, VAT is not charged.

For all customers who do have a valid French VAT number: Opération bénéficiant du régime d’auto-liquidation prévu par l’article 283-1 du CGI; TVA due par le client.

Additional information:All ECIO 2015 registrants will be able to print out an invoice of registration using their personal login details at www.ecio.org.

Invoices will be issued by: CIRSE Congress Research Education GmbH, Neutorgasse 9, 1010 Vienna, Austria

Cancellation of congress registrationCIRSE GmbH offers all pre-registered participants the possibi li-ty to take out cancellation insurance with its partner „Europäi-sche Reiseversicherung“. The insurance can only be booked during and until finalisation of the online registration process. The refund of the participant‘s registration fee due to cancellation of the registration or the change of registration category is only possible with a valid insurance. CIRSE GmbH itself will not refund any registration fees. All requests must be made to „Europäische Reiseversicherung“ directly. Refunds will be given according to the terms and conditions of the „Europäische Reiseversicherung“. CIRSE GmbH shall not be responsible for any refunds of registration fees.

Name changes will be handled as a cancellation and newregistration.

** Registration needs to be accompanied by a confirmation of student status at the time of congress, a one page CV and a copy of a valid photo ID.


In cooperation with our travel partner Kuoni DMC, CIRSE has secured a great number of hotel rooms in Nice for the benefit of our congress participants. For further information about the official CIRSE hotels and room bookings, please refer to www.ecio.org.

If you have any questions, please do not hesitate to contact:Kuoni Destination Management FRContact: Ms Sophie Veyrier31 avenue Jean Médecin06000 Nice, FrancePhone: +33 1 55 99 98 98E-mail: [email protected]

Accommodation

24 Accommodation / City Map

Nice City Map


1

5 2

3

Tram Station “Opéra - Vieille Ville“

Tram Station “Acropolis“

AcropolisConventionCentre

7

46

List of hotels

Hotel Category Single Room (€) Double Room (€) Travel Time Public Transport Taxi

1 Negresco 5* 274.50 291.00 25 min 7 min2 Hôtel Beau Rivage 4* 156.50 168.00 10 min 5 min3 Grand Hotel Aston 4* 156.50 168.00 5 min 5 min4 NH Hotel 4* 161.50 178.00 5 min walk 5 Le Méridien Nice (Classic Room) 4* 192.50 210.00 10 min 5 min Le Méridien Nice (Deluxe City View) 4* 237.50 252.00 10 min 5 min6 Novotel Acropolis 4* 147.50 166.00 4 min walk 7 Ibis Palais des Congrès 3* 108.00 119.00 9 min walk

All rates are in Euros (€), per room, per night, including breakfast and taxes.

Preliminary Programme ECIO 2015In case of any enquiries or comments, please contact us at [email protected]

© Cardiovascular and Interventional Radiological Society of Europe / 2014

CIRSE does not accept responsibility for errors or misprints.

GraphX by L O O P . E N T E R P R I S E S mediawww.loop-enterprises.com

Print kompensiertwww.druckmedien.at

The European Conference on Interventional Oncology is organised by CIRSE (Cardiovascular and Interventional Radiological Society of Europe). The official congress website is: www.ecio.org To contact the CIRSE Central Office or members of the committee please write to [email protected].


Documents

LEADERS IN ONCOLOGIC INTERVENTIONS ECIO 2015€¦ · learning. The Video Learning Sessions, whose debut in 2014 was well received, will be featured again this year, addressing liver,